Literature DB >> 22205584

Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models.

Paul R Kinchington1, William F Goins.   

Abstract

Pain and post-herpetic neuralgia (PHN) are common and highly distressing complications of herpes zoster that remain a significant public health concern and in need of improved therapies. Zoster results from reactivation of the herpesvirus varicella zoster virus (VZV) from a neuronal latent state established at the primary infection (varicella). PHN occurs in some one fifth to one third of zoster cases with severity, incidence, and duration of pain increasing with rising patient age. While VZV reactivation and the ensuing ganglionic damage trigger the pain response, the mechanisms underlying protracted PHN are not understood, and the lack of an animal model of herpes zoster (reactivation) makes this issue more challenging. A recent preclinical rodent model has developed that opens up the potential to allow the exploration of the underlying mechanisms and treatments for VZV-induced pain. Rats inoculated with live cell-associated human VZV into the hind paw reliably demonstrate thermal hyperalgesia and mechanical allodynia for extended periods and then spontaneously recover. Dorsal root ganglia express a limited VZV gene subset, including the IE62 regulatory protein, and upregulate expression of markers suggesting a neuropathic pain state. The model has been used to investigate treatment modalities and aspects of pain signaling and is under investigation by the authors to delineate VZV genetics involved in the induction of pain. This article compares human zoster-associated pain and PHN to the pain indicators in the rat and poses important questions that, if answered, could be the basis for new treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205584      PMCID: PMC3946975          DOI: 10.1007/s13365-011-0069-7

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


  81 in total

Review 1.  Varicella vaccine effectiveness in the US vaccination program: a review.

Authors:  Jane F Seward; Mona Marin; Marietta Vázquez
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

2.  Post-herpetic neuralgia: post-mortem analysis of a case.

Authors:  C P N Watson; C Morshead; D Van der Kooy; J Deck; R J Evans
Journal:  Pain       Date:  1988-08       Impact factor: 6.961

3.  Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.

Authors:  F S Hasnie; J Breuer; S Parker; V Wallace; J Blackbeard; I Lever; P R Kinchington; A H Dickenson; T Pheby; A S C Rice
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

Review 4.  Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.

Authors:  Ann M Arvin; Jennifer F Moffat; Marvin Sommer; Stefan Oliver; Xibing Che; Susan Vleck; Leigh Zerboni; Chia-Chi Ku
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 5.  Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.

Authors:  Anne A Gershon; Michael D Gershon; Judith Breuer; Myron J Levin; Anne Louise Oaklander; Paul D Griffiths
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

6.  Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older.

Authors:  S K Tyring; K R Beutner; B A Tucker; W C Anderson; R J Crooks
Journal:  Arch Fam Med       Date:  2000 Sep-Oct

7.  Drug testing for activity against varicella-zoster virus in hairless guinea pigs.

Authors:  M G Myers; L R Stanberry
Journal:  Antiviral Res       Date:  1991-05       Impact factor: 5.970

8.  Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia.

Authors:  Georges M G M Verjans; Rogier Q Hintzen; Jessica M van Dun; Angelique Poot; Johannes C Milikan; Jon D Laman; Anton W Langerak; Paul R Kinchington; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 9.  Herpes zoster antivirals and pain management.

Authors:  Deborah Pavan-Langston
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079

Review 10.  Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence.

Authors:  Michael N Oxman
Journal:  J Am Osteopath Assoc       Date:  2009-06
View more
  17 in total

Review 1.  Latent versus productive infection: the alpha herpesvirus switch.

Authors:  Orkide O Koyuncu; Margaret A MacGibeny; Lynn W Enquist
Journal:  Future Virol       Date:  2018-05-22       Impact factor: 1.831

Review 2.  Molecular mechanisms of varicella zoster virus pathogenesis.

Authors:  Leigh Zerboni; Nandini Sen; Stefan L Oliver; Ann M Arvin
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

3.  Lateral thalamic control of nociceptive response after whisker pad injection of varicella zoster virus.

Authors:  Phillip R Kramer; Crystal Stinson; Mikhail Umorin; Mohong Deng; Mahesh Rao; Larry L Bellinger; Michael B Yee; Paul R Kinchington
Journal:  Neuroscience       Date:  2017-05-24       Impact factor: 3.590

4.  Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia.

Authors:  Jean-Marc G Guedon; Michael B Yee; Mingdi Zhang; Stephen A K Harvey; William F Goins; Paul R Kinchington
Journal:  Virology       Date:  2015-04-11       Impact factor: 3.616

5.  Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge.

Authors:  Christine Meyer; Flora Engelmann; Nicole Arnold; David L Krah; Jan ter Meulen; Kristen Haberthur; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

6.  The ORF61 Protein Encoded by Simian Varicella Virus and Varicella-Zoster Virus Inhibits NF-κB Signaling by Interfering with IκBα Degradation.

Authors:  Travis Whitmer; Daniel Malouli; Luke S Uebelhoer; Victor R DeFilippis; Klaus Früh; Marieke C Verweij
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

7.  Neurexin 3α in the Central Amygdala has a Role in Orofacial Varicella Zoster Pain.

Authors:  Phillip R Kramer; Mikhail Umorin; Rebecca Hornung; Paul R Kinchington
Journal:  Neuroscience       Date:  2022-06-06       Impact factor: 3.708

8.  Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin.

Authors:  J-M G Guedon; M Zhang; J C Glorioso; W F Goins; P R Kinchington
Journal:  Gene Ther       Date:  2014-05-15       Impact factor: 5.250

Review 9.  Current gene therapy using viral vectors for chronic pain.

Authors:  Jean-Marc G Guedon; Shaogen Wu; Xuexing Zheng; Caroline C Churchill; Joseph C Glorioso; Ching-Hang Liu; Shue Liu; Lucy Vulchanova; Alex Bekker; Yuan-Xiang Tao; Paul R Kinchington; William F Goins; Carolyn A Fairbanks; Shuanglin Hao
Journal:  Mol Pain       Date:  2015-05-13       Impact factor: 3.395

10.  Varicella-zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line.

Authors:  Peter G E Kennedy; Paul Montague; Fiona Scott; Esther Grinfeld; G H Ashrafi; Judith Breuer; Edward G Rowan
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.